1. Home
  2. GENK vs BOLT Comparison

GENK vs BOLT Comparison

Compare GENK & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GEN Restaurant Group Inc.

GENK

GEN Restaurant Group Inc.

HOLD

Current Price

$2.02

Market Cap

12.8M

ML Signal

HOLD

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

HOLD

Current Price

$3.97

Market Cap

7.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GENK
BOLT
Founded
2011
2015
Country
United States
United States
Employees
2700
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8M
7.3M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
GENK
BOLT
Price
$2.02
$3.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$4.50
$34.00
AVG Volume (30 Days)
11.7K
16.8K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
1.88%
N/A
EPS Growth
62.50
N/A
EPS
N/A
N/A
Revenue
$208,380,000.00
$7,695,000.00
Revenue This Year
$4.79
N/A
Revenue Next Year
$7.48
$133.33
P/E Ratio
N/A
N/A
Revenue Growth
15.12
0.07
52 Week Low
$1.43
$3.75
52 Week High
$4.29
$7.20

Technical Indicators

Market Signals
Indicator
GENK
BOLT
Relative Strength Index (RSI) 58.54 47.76
Support Level $1.71 $3.90
Resistance Level $2.18 $4.46
Average True Range (ATR) 0.13 0.24
MACD 0.02 0.01
Stochastic Oscillator 89.53 39.10

Price Performance

Historical Comparison
GENK
BOLT

About GENK GEN Restaurant Group Inc.

GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

Share on Social Networks: